Pediatrix Medical Group, Inc. Stock Price, News & Analysis

Oteemo, Inc. has successfully assisted Mednax, Inc. (NYSE: MD) in significantly reducing its application deployment time from months to minutes by implementing a DevSecOps practice. This initiative aims to enhance Mednax's IT capabilities, which support high-quality patient care. The collaboration fosters a culture shift at Mednax, focusing on a product-oriented mindset and measurable engineering practices. Senior Director Adam Martin emphasized the partnership's role in integrating innovation to better serve patients.

Mednax, Inc. (NYSE: MD) has announced its affiliation with NightLight Pediatric Urgent Care, based in Houston. This partnership marks the start of a new strategy aimed at enhancing pediatric care, incorporating urgent, primary, and telehealth services. Mednax plans to expand NightLight's existing services, offering a comprehensive pediatric continuum, including subspecialties and wellness programs. The cash transaction is expected to be immediately accretive to earnings. NightLight, operational since 2007, serves over 90,000 patients annually across eight locations in Houston.

Mednax, Inc. (NYSE: MD) announced two investor presentations scheduled for February 25 and March 1, 2021. The company will present at Citi’s 2021 Healthcare Services Conference at 2:25 p.m. ET and at the J.P. Morgan Global High Yield & Leveraged Finance Conference at 10:00 a.m. ET. Both presentations will be available via live audio webcasts. Established in 1979, Mednax is a national medical group with over 2,300 physicians operating in 39 states and Puerto Rico, focusing on enhancing patient care and outcomes through innovative practices.

Mednax, Inc. (NYSE: MD) reported earnings of $0.05 per share for Q4 2020, with adjusted EPS of $0.25. The company's net revenue for the quarter was $417 million, down from $458.6 million in Q4 2019. Mednax's overall same-unit revenue declined by 9.5%, impacted by the COVID-19 pandemic. For the full year, revenue from continuing operations was $1.73 billion, a decrease from $1.78 billion in 2019. Mednax ended the year with $1.12 billion in cash. CEO Mark S. Ordan expressed confidence in the company's future post-COVID, focusing on efficiency and financial strength.

Mednax, Inc. (NYSE: MD) will hold an investor conference call on February 18, 2021, at 9:00 a.m. ET to discuss operational results for the year ended December 31, 2020. A detailed press release will be issued before the conference. Mednax is a national health solutions partner, providing services through over 2,300 physicians in 39 states and Puerto Rico, focusing on enhancing patient outcomes with evidence-based tools and telehealth programs.

Mednax, Inc. (NYSE: MD) will host NEO: The Conference for Neonatology from Feb. 15-19, 2021. This virtual event, now in its 42^nd year, aims to provide essential insights into neonatal management to enhance newborn outcomes. Co-directed by Drs. Reese Clark and Timothy Biela, it features an expert panel discussing critical issues, including COVID-19 preparation in NICUs. Participants can earn up to 19.0 AMA PRA Category 1 Credits. The Legends of Neonatology Award will honor Robert Christensen, M.D. for his contributions to neonatal medicine.

The law firm Federman & Sherwood has initiated a data breach lawsuit against MedNax (NYSE: MD) and its subsidiary, Pediatrix Medical Group. The lawsuit addresses potential violations of consumer laws stemming from a data breach disclosed by MedNax on December 16, 2020. The breach reportedly involved unauthorized access to sensitive personal and medical data from Microsoft Office 365 accounts. This may include patient names, Social Security numbers, health insurance details, and medical records.

MEDNAX, Inc. (NYSE: MD) has successfully finalized the sale of MEDNAX Radiology Solutions to Radiology Partners for $885 million, netting approximately $865 million after expenses. This strategic move allows MEDNAX to concentrate on its core services for women, newborns, and children. The proceeds will be used to redeem $750 million of senior notes due in 2023, among other corporate purposes. This transaction strengthens MEDNAX's balance sheet as it prepares for future growth.

MEDNAX reported a net loss of $41 million or $0.49 per share for Q3 2020, impacted mainly by a non-cash loss from the MEDNAX Radiology Solutions classification. Adjusted EPS from continuing operations was $0.37. Total revenue stood at $461 million, with same-unit patient volumes declining by 4.3%. The company also announced the sale of MEDNAX Radiology Solutions, aiming to focus on core pediatric and obstetric services. Despite a loss from continuing operations of $2.7 million, cash inflow from operations was $127.1 million, reflecting a solid financial position amidst COVID-19 challenges.